Prior human studies in MASLD have shown increased baseline IL-6, IL-17A and TGF-β1 which are associated with hepatic inflammation, insulin resistance, and fibrosis [26,27]. This evidence concerns the gene IL6 and metabolic dysfunction-associated steatotic liver disease.